The clinical effectiveness and cost- effectiveness of screening for age-related macular degeneration in Japan: A Markov modeling study

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Tamura, Hiroshi ^a,b   Goto, Rei ^c,d   Akune, Yoko ^e   Hiratsuka, Yoshimune ^f   Hiragi, Shusuke ^a   Yamada, Masakazu ^g  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^f NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^g KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN ANTIBODY;

ADULT; AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MASS SCREENING; MORBIDITY; PHOTODYNAMIC THERAPY; PREVALENCE; PROBABILITY; PRODROMAL SYMPTOM; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; AGED; COST BENEFIT ANALYSIS; FEMALE; HEALTH CARE COST; MACULAR DEGENERATION; MALE; MARKOV CHAIN; MIDDLE AGED; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; JAPAN; MACULAR DEGENERATION; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; MORBIDITY; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84941903245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133628     Document Type: Article

References (64)

1. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, et al. Racial differences in the causespecific prevalence of blindness in east Baltimore. N Engl J Med. 1991; 325(20):1412-7. doi: 10.1056/NEJM199111143252004 PMID: 1922252.
2. Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: The Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2000; 28 (4):268-73. Epub 2000/10/06. PMID: 11021555.
3. Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol. 2000; 118(2):264-9. Epub 2000/02/17. PMID: 10676793.
4. Munoz B, West SK, Rubin GS, Schein OD, Quigley HA, Bressler SB, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000; 118(6):819-25. Epub 2000/06/24. PMID: 10865321.
5. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam Study. Arch Ophthalmol. 1998; 116(5):653-8. Epub 1998/05/22. PMID: 9596502.
6. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995; 36(1):182-91. Epub 1995/01/01. PMID: 7822146.
7. Nakae K MK, Senoo T, Sawa M, Kanai A, Ishibashi T. Aging society and eye disease: A recent epidemiological study on underlying diseases responsible for visual impairment [in Japanese]. Geriatr Med. 2006; 44:1221-4.
8. Wako R, Yasukawa T, Kato A, Omori T, Ishida S, Ishibashi T, et al. Causes and prevalence of visual impairment in Japan [in Japanese] Nippon Ganka Gakkai Zasshi. 2014; 118(6):495-501. PMID: 25016791.
9. Jager RD, Mieler WF, Miller JW. Age-Related Macular Degeneration. New England Journal of Medicine. 2008; 358(24):2606-17. doi: 10.1056/NEJMra0801537 PMID: 18550876.
10. Mori K, Horie-Inoue K, Gehlbach PL, Takita H, Kabasawa S, Kawasaki I, et al. Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology. 2010; 117(5):928-38. Epub 2010/02/06. doi: 10.1016/j.ophtha.2009.10.001 PMID: 20132989.
11. Nakata I, Yamashiro K, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: The Nagahama study. Am J Ophthalmol. 2013; 156(5):1002-9 e2. doi: 10.1016/j.ajo.2013.06.007 PMID: 23938127.
12. Tamura H, Tsujikawa A, Yamashiro K, Akagi-Kurashige Y, Nakata I, Nakanishi H, et al. Association of ARMS2 genotype with bilateral involvement of exudative age-related macular degeneration. Am J Ophthalmol. 2012; 154(3):542-8 e1. doi: 10.1016/j.ajo.2012.03.042 PMID: 22809783.
13. Uyama M, Takahashi K, Ida N, Miyashiro M, Ando A, Takahashi A, et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol. 2000; 84 (9):1018-23. Epub 2000/09/01. PMID: 10966957; PubMed Central PMCID: PMC1723651.
14. Ueta T, Iriyama A, Francis J, Takahashi H, Adachi T, Obata R, et al. Development of typical age-related macular degeneration and polypoidal choroidal vasculopathy in fellow eyes of Japanese patients with exudative age-related macular degeneration. Am J Ophthalmol. 2008; 146(1):96-101. Epub 2008/04/29. doi: 10.1016/j.ajo.2008.03.002 PMID: 18439567.
15. Mitchell P, Annemans L, White R, Gallagher M, Thomas S. Cost effectiveness of treatments for wet age-related macular degeneration. PharmacoEconomics. 2011; 29(2):107-31. Epub 2011/01/20. doi: 10.2165/11585520-000000000-00000 PMID: 21244102.
16. Cohen SY, Bremond-Gignac D, Quentel G, Mimoun G, Citterio T, Bisot-Locard S, et al. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2008; 246(11):1527-34. doi: 10.1007/s00417-008-0890-8 PMID: 18642019.
17. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost effectiveness and resource allocation: C/E. 2008; 6(1):12. doi: 10.1186/1478-7547-6-12 PMID: 18573218; PubMed Central PMCID: PMC2443361.
18. Group AHSR, Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014; 121(2):535-44. Epub 2013/11/12. doi: 10.1016/j.ophtha.2013. 10.027 PMID: 24211172; PubMed Central PMCID: PMC3918479.
19. Kanagasingam Y, Bhuiyan A, Abramoff MD, Smith RT, Goldschmidt L, Wong TY. Progress on retinal image analysis for age related macular degeneration. Progress in retinal and eye research. 2014; 38:20-42. Epub 2013/11/12. doi: 10.1016/j.preteyeres.2013.10.002 PMID: 24211245.
20. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. Jama. 1994; 272(18):1413-20. Epub 1994/11/09. PMID: 7933422.
21. The Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. Jama. 2013; 309(19):2005-15. Epub 2013/05/07. doi: 10.1001/jama.2013.4997 PMID: 23644932.
22. Krishnadev N, Meleth AD, Chew EY. Nutritional supplements for age-related macular degeneration. Curr Opin Ophthalmol. 2010; 21(3):184-9. Epub 2010/03/11. doi: 10.1097/ICU.0b013e32833866ee PMID: 20216418; PubMed Central PMCID: PMCPMC2909501.
23. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 2008; 115(6):1039-45 e5. doi: 10.1016/j.ophtha.2007.08.033 PMID: 17976724.
24. Fletcher EC, Lade RJ, Adewoyin T, Chong NV. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology. 2008; 115(12):2192-8. doi: 10.1016/j. ophtha.2008.07.018 PMID: 18930556.
25. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999; 97:473-511. PMID: 10703139; PubMed Central PMCID: PMC1298275.
26. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value in health: The journal of the International Society for Pharmacoeconomics and Outcomes Research. 2001; 4(5):348-61. doi: 10.1046/j.1524- 4733.2001.45061.x PMID: 11705125.
27. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997; 336(5):332-6. doi: 10.1056/NEJM199701303360503 PMID: 9011785.
28. Eye Care Comparative Effectiveness Research Team (ECCERT), Hiratsuka Y, Yamada M, Akune Y, Murakami A, Okada AA, et al. Cost-utility analysis of cataract surgery in Japan: A probabilistic Markov modeling study. Jpn J Ophthalmol. 2013; 57(4):391-401. doi: 10.1007/s10384-013-0238-8 PMID: 23588297.
29. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001; 108(11):2051-9. doi: 10.1016/S0161-6420(01)00764-3 PMID: 11713079.
30. Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: The Hisayama study. Br J Ophthalmol. 2001; 85 (10):1153-7. doi: 10.1136/bjo.85.10.1153 PMC1723746. PMID: 11567955.
31. Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009; 116(11):2135-40. Epub 2009/09/12. doi: 10.1016/j.ophtha.2009.04.017 PMID: 19744734.
32. Uyama M, Takahashi K, Ida N, Miyashiro M, Ando A, Takahashi A, et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol. 2000; 84 (9):1018-23. Epub 2000/09/01. PMID: 10966957; PubMed Central PMCID: PMC1723651.
33. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. PMID: 17021318.
34. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007; 144(1):15-22. doi: 10.1016/j.ajo.2007. 03.047 PMID: 17509509.
35. Holden BA, Fricke TR, Ho SM, Wong R, Schlenther G, Cronje S, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol. 2008; 126(12):1731-9. doi: 10.1001/archopht.126.12.1731 PMID: 19064856.
36. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000; 118(1):47-51. PMID: 10636413.
37. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-44. doi: 10. 1056/NEJMoa062655 PMID: 17021319.
38. Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. British Journal of Ophthalmology. 2012; 96(12):1469-73. doi: 10.1136/bjophthalmol-2012-302167 PMID: 23001255.
39. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012; 119(8):1609-14. doi: 10. 1016/j.ophtha.2012.02.014 PMID: 22480743.
40. Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T, et al. Risk factors for age related maculopathy in a Japanese population: The Hisayama study. Br J Ophthalmol. 2003; 87(4):469-72. PMID: 12642312; PubMed Central PMCID: PMC1771615.
41. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999; 117 (10):1329-45. Epub 1999/10/26. PMID: 10532441.
42. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001; 119(2):198-207. Epub 2001/02/15. PMID: 11176980.
43. Neubauer AS, Holz FG, Sauer S, Wasmuth T, Hirneiss C, Kampik A, et al. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system. Clin Ther. 2010; 32(7):1343-56. doi: 10.1016/j.clinthera.2010.07.010 PMID: 20678682.
44. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine. 2006; 355 (14):1432-44. PMID: 17021319.
45. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897-908. doi: 10.1056/NEJMoa1102673 PMID: 21526923; PubMed Central PMCID: PMC3157322.
46. Tano Y, Ohji M, Group E-IS. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol. 2010; 88(3):309-16. doi: 10.1111/j.1755-3768.2009.01843.x PMID: 20163368.
47. Antoszyk AN, Tuomi L, Chung CY, Singh A, Group FS. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008; 145(5):862-74. Epub 2008/03/07. doi: 10.1016/j.ajo.2007.12.029 PMID: 18321465.
48. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145(2):239-48. doi: 10.1016/j.ajo.2007.10.004 PMID: 18222192.
49. Bressler NM, Bressler SB, Congdon NG, Ferris FL 3rd, Friedman DS, Klein R, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003; 121(11):1621-4. Epub 2003/11/12. doi: 10.1001/archopht.121.11.1621 PMID: 14609922; PubMed Central PMCID: PMCPMC1473209.
50. Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, Hsia J, et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age- Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA internal medicine. 2014; 174 (5):763-71. Epub 2014/03/19. doi: 10.1001/jamainternmed.2014.328 PMID: 24638908.
51. Takahashi K, Ogura Y, Ishibashi T, Shiraga F, Yuzawa M. Treatment guidelines for age-related macular degeneration [in Japanese]. Nihon Ganka Gakkai Zasshi. 2012; 116(12):1150-5. Epub 2013/02/06. PMID: 23379205.
52. Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015; 99(2):220-6. doi: 10.1136/bjophthalmol-2014-305327 PMID: 25193672; PubMed Central PMCID: PMC4316940.
53. Pineles SL, Birch EE, Talman LS, Sackel DJ, Frohman EM, Calabresi PA, et al. One eye or two: A comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol. 2011; 152(1):133-40. doi: 10.1016/j.ajo.2011.01.023 PMID: 21570055; PubMed Central PMCID: PMC3637955.
54. Hirneiss C. The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life. Clinical ophthalmology. 2014; 8:1703-9. doi: 10.2147/OPTH.S64200 PMID: 25214763; PubMed Central PMCID: PMC4159393.
55. Japan Ophthalmologists Association. Social burden of visual disturbance in Japan [in Japanese]. 2009.
56. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-topay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health economics. 2010; 19(4):422-37. Epub 2009/04/22. doi: 10.1002/hec.1481 PMID: 19382128.
57. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012; 153(2):209-13 e2. doi: 10.1016/j.ajo.2011.10. 016 PMID: 22264944.
58. Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology. 2007; 114(6):1170-8. doi: 10.1016/j.ophtha.2006.09.019 PMID: 17320964.
59. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther. 2008; 30(12):2436-51. doi: 10.1016/j.clinthera.2008.12.025 PMID: 19167602.
60. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010; 248(4):467-76. doi: 10.1007/s00417-009-1156-9 PMID: 19669678.
61. Hiratsuka Y, Yamada M, Akune Y, Murakami A, Okada AA, Yamashita H, et al. Assessment of visionrelated quality of life among patients with cataracts and the outcomes of cataract surgery using a newly developed visual function questionnaire: The VFQ-J11. Jpn J Ophthalmol. 2014; 58(5):415-22. doi: 10. 1007/s10384-014-0335-3 PMID: 25037865.
62. Yanagi Y, Aihara Y, Fukuda T, Hashimoto H. Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration [in Japanese]. Nihon Ganka Gakkai Zasshi. 2011; 115(9):825-31. PMID: 22073599.
63. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120(11):2292-9. Epub 2013/05/07. doi: 10.1016/j.ophtha.2013.03.046 PMID: 23642856.
64. Kawasaki R, Akune Y, Hiratsuka Y, Fukuhara S, Yamada M. Cost-utility analysis of screening for diabetic retinopathy in Japan: A probabilistic Markov modeling study. Ophthalmic epidemiology. 2015; 22 (1): 4-12. Epub 2014/12/18. doi: 10.3109/09286586.2014.988876 PMID: 25517603.